<DOC>
	<DOCNO>NCT00111566</DOCNO>
	<brief_summary>This trial design examine efficacy brief versus standard prolong ( 18 hour ) infusion eptifibatide prevent troponin I release follow successful coronary stenting .</brief_summary>
	<brief_title>BRIEF-PCI : Brief Infusion Eptifibatide Following Percutaneous Coronary Intervention</brief_title>
	<detailed_description>Percutaneous coronary intervention ( PCI ) common treatment patient severe ischemic heart disease . In majority case , potent anti-platelet agent eptifibatide administer ( bolus follow infusion 18 hour ) . The principal reason use eptifibatide PCI prevent platelet aggregation associate ischemia myocardial infarction ( MI ) . With improved laminar flow follow stenting , prolonged infusion eptifibatide may longer necessary . We hypothesize successful stenting good angiographic result , patient eptifibatide discontinue immediately without high risk adverse ischemic outcome , i.e . death , MI unplanned target vessel revascularization ( TVR ) 30 day . MI define creatine kinase-MB ( CK-MB ) concentration elevate three time upper limit normal new pathologic Q wave see electrocardiogram ( ECG ) . In order prove hypothesis , estimate sample size 2,100 patient . Before embark large-scale clinical trial , propose pilot study use serum troponin I elevation surrogate end-point . Troponin I sensitive biomarker ischemic injury . The absence troponin I release follow PCI would suggest excellent short intermediate term prognosis . For pilot study , seek prove hypothesis follow successful PCI stenting , abbreviate regimen eptifibatide inferior standard infusion prevent ischemic injury , define troponin I release baseline value normal , CK-MB 3 time upper limit normal baseline troponin I elevate . For pilot study , estimate sample size 620 patient .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Eptifibatide</mesh_term>
	<criteria>Male nonpregnant female subject 18 year age old Received aspirin , clopidogrel , heparin ( unfractionated low molecular weight [ LMW ] ) eptifibatide Had successful PCI procedure least one stent deploy Availability hospital bed Use alternative antithrombin therapy PCI ( e.g . bivalirudin ) High risk patient : Acute ST elevation MI &lt; 48 hour ( either direct PCI rescue PCI ) Unprotected left main PCI Obvious large thrombus angiography Use rotablation , atherectomy , thrombectomy device Unsatisfactory PCI result : Final thrombolysis myocardial infarction ( TIMI ) flow &lt; 3 High grade dissection ( &gt; type B , completely resolve completion PCI ) Evident suspect thrombus Distal embolization Suboptimal stenting ( &gt; 20 % residual stenosis ) Side branch closure ( â‰¥ 1.5 mm branch associate symptom ) Abrupt closure procedure ( prolonged &gt; 15 min resolve completion PCI ) Clinical instability Prolonged ischemia PCI ( &gt; 15 min ) Increased hazard eptifibatide infusion : Unsatisfactory deployment closure device ( use ) Large periprocedure hematoma make continuation eptifibatide hazardous Any condition increase hazard continue eptifibatide Operator discretion No inform consent Active participation research study ( unless special exemption )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Percutaneous Coronary Intervention ( PCI )</keyword>
	<keyword>Glycoprotein IIb/IIIa blockade</keyword>
	<keyword>Ischemic complication follow PCI</keyword>
</DOC>